Staphylococcus aureus broncho-pulmonary infections;Infections broncho-pulmonaires à Staphylococcus aureus

Revue de Pneumologie Clinique

Volumn 69, Issue 6, 2013, Pages 368-382

  Valour, F ^a,b,c,d   Chebib, N ^a   Gillet, Y ^b,c,d   Reix, P ^b,e   Laurent, F ^b,c,d   Chidiac, C ^a,b,c,d   Ferry, T ^a,b,c,d  

^a CROIX ROUSSE HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e Service de Pneumologie   (France)

Author keywords

Broncho pulmonary infection; Hospital acquired pneumonia; Panton Valentin leukocidin; Staphylococcus aureus

Indexed keywords

CLINDAMYCIN; IMMUNOGLOBULIN; LINEZOLID; PANTON VALENTINE LEUKOCIDIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; STAPHYLOCOCCUS TOXIN;

ANTIBIOTIC SENSITIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CYSTIC FIBROSIS; DEATH; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; HEMOPTYSIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFLUENZA; LEUKOPENIA; MORTALITY; NECROTIZING PNEUMONIA; PENICILLIN RESISTANCE; PNEUMONIA; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VIRAL RESPIRATORY TRACT INFECTION;

BRONCHO-PULMONARY INFECTION; HOSPITAL-ACQUIRED PNEUMONIA; LEUCOCIDINE DE PANTON-VALANTINE; PANTON-VALENTIN LEUKOCIDIN; PNEUMOPATHIE; PNEUMOPATHIE NOCOCOMIALE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BRONCHOPNEUMONIA; HUMANS; LUNG DISEASES; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84890148766     PISSN: 07618417     EISSN: 17762561     Source Type: Journal    
DOI: 10.1016/j.pneumo.2013.08.004     Document Type: Review

References (100)

1. Lowy F.D. Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
2. Vandenesch F., Naimi T., Enright M.C., Lina G., Nimmo G.R., Heffernan H., et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978-984.
3. Gillet Y., Issartel B., Vanhems P., Fournet J.C., Lina G., Bes M., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
4. Koulenti D., Lisboa T., Brun-Buisson C., Krueger W., Macor A., Sole-Violan J., et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009, 37:2360-2368.
5. Meyer E., Schwab F., Gastmeier P. Nosocomial methicillin resistant Staphylococcus aureus pneumonia-epidemiology and trends based on data of a network of 586German ICUs (2005-2009). Eur J Med Res 2010, 15:514-524.
6. Ferry T., Perpoint T., Vandenesch F., Étienne J. Virulence determinants in Staphylococcus aureus and their involvement in clinical syndromes. Curr Infect Dis Rep 2005, 7:420-428.
7. Parker D., Prince A. Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin Immunopathol 2012, 34:281-297.
8. Leemans J.C., Heikens M., van Kessel K.P., Florquin S., van der Poll T. Lipoteichoic acid and peptidoglycan from Staphylococcus aureus synergistically induce neutrophil influx into the lungs of mice. Clin Diagn Lab Immunol 2003, 10:950-953.
9. Kahl B.C., Goulian M., van Wamel W., Herrmann M., Simon S.M., Kaplan G., et al. Staphylococcus aureus RN6390replicates and induces apoptosis in a pulmonary epithelial cell line. Infect Immun 2000, 68:5385-5392.
10. Goerke C., Wolz C. Adaptation of Staphylococcus aureus to the cystic fibrosis lung. Int J Med Microbiol 2010, 300:520-525.
11. Alp E., Guven M., Yildiz O., Aygen B., Voss A., Doganay M. Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study. Ann Clin Microbiol Antimicrob 2004, 3:17.
12. Torres A., Ewig S., Lode H., Carlet J. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 2009, 35:9-29.
13. Holmes A., Ganner M., McGuane S., Pitt T.L., Cookson B.D., Kearns A.M. Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. J Clin Microbiol 2005, 43:2384-2390.
14. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. Methicillin-resistant S.aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
15. von Eiff C., Friedrich A.W., Peters G., Becker K. Prevalence of genes encoding for members of the staphylococcal leukotoxin family among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis 2004, 49:157-162.
16. Perbet S., Soummer A., Vinsonneau C., Vandebrouck A., Rackelboom T., Etienne J., et al. Multifocal community-acquired necrotizing fasciitis caused by a Panton-Valentine leukocidin-producing methicillin-sensitive Staphylococcus aureus. Infection 2010, 38:223-225.
17. Gillet Y., Dohin B., Dumitrescu O., Lina G., Vandenesch F., Étienne J., et al. Osteoarticular infections with Staphylococcus aureus secreting Panton-Valentine leucocidin. Arch Pediatr 2007, 14:S102-S107.
18. Niemann S., Ehrhardt C.E.M., Warnking K., Tuchscherr L., Heitmann V., et al. Combined action of Influenza virus and Staphylococcus aureus Panton-Valentine leukocidin provokes severe lung epithelium damage. J Infect Dis 2012, 206:1138-1148.
19. Miles G., Movileanu L., Bayley H. Subunit composition of a bicomponent toxin: staphylococcal leukocidin forms an octameric transmembrane pore. Protein Sci 2002, 11:894-902.
20. Labandeira-Rey M., Couzon F., Boisset S., Brown E.L., Bes M., Benito Y., et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007, 315:1130-1133.
21. Wu Q., Gui P., Yao S., Zhu H., Li J., Li Y. Expression of beta-defensin-3in lungs of immunocompetent rats with methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia. J Surg Res 2011, 169:277-283.
22. Kluytmans J., van Belkum A., Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997, 10:505-520.
23. Wertheim H.F., Melles D.C., Vos M.C., van Leeuwen W., van Belkum A., Verbrugh H.A., et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005, 5:751-762.
24. Laupland K.B., Gregson D.B., Flemons W.W., Hawkins D., Ross T., Church D.L. Burden of community-onset bloodstream infection: a population-based assessment. Epidemiol Infect 2007, 135:1037-1042.
25. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated, pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
26. Ede S., Davis G.M., Holmes F.H. Staphylococcic pneumonia. J Am Med Assoc 1959, 170:638-643.
27. File T.M. Community-acquired pneumonia. Lancet 2003, 362:1991-2001.
28. Hausmann W., Karlish A.J. Staphylococcal pneumonia in adults. Br Med J (Clin Res Ed) 1956, 2:845-847.
29. Rebhan A.W., Edwards H.E. Staphylococcal pneumonia: a review of 329cases. Can Med Assoc J 1960, 82:513-517.
30. Chickering H.T., Park J.H.J. Staphylococcus aureus pneumonia. JAMA 1919, 72:617.
31. Gillet Y., Vanhems P., Lina G., Bes M., Vandenesch F., Floret D., et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007, 45:315-321.
32. Lina G., Piemont Y., Godail-Gamot F., Bes M., Peter M.O., Gauduchon V., et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128-1132.
33. Benhamou D., Carrie A.S., Lecomte F. [Staphylococcus aureus: role and impact in the treatment of nosocomial pneumonia]. Rev Mal Respir 2005, 22:595-603.
34. Rello J., Molano D., Villabon M., Reina R., Rita-Quispe R., Previgliano I., et al. Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: A comparison of the EUVAP and LATINVAP study cohorts. Med Intensiva 2012, 37:241-247.
35. Esperatti M., Ferrer M., Theessen A., Liapikou A., Valencia M., Saucedo L.M., et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 2010, 182:1533-1539.
36. Sopena N., Sabria M. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest 2005, 127:213-219.
37. Weber D.J., Rutala W.A., Sickbert-Bennett E.E., Samsa G.P., Brown V., Niederman M.S. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007, 28:825-831.
38. Hageman J.C., Uyeki T.M., Francis J.S., Jernigan D.B., Wheeler J.G., Bridges C.B., et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04influenza season. Emerg Infect Dis 2006, 12:894-899.
39. Kallen A.J., Brunkard J., Moore Z., Budge P., Arnold K.E., Fosheim G., et al. Staphylococcus aureus community-acquired pneumonia during the 2006to 2007influenza season. Ann Emerg Med 2009, 53:358-365.
40. Anevlavis S., Petroglou N., Tzavaras A., Maltezos E., Pneumatikos I., Froudarakis M., et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009, 59:83-89.
41. Endimiani A., Hujer K.M., Hujer A.M., Kurz S., Jacobs M.R., Perlin D.S., et al. Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?. Clin Infect Dis 2011, 52:S373-S383.
42. Peterson L.R. Molecular laboratory tests for the diagnosis of respiratory tract infection due to Staphylococcus aureus. Clin Infect Dis 2011, 52:S361-S366.
43. Banthia S., Meka V.G., Pillai S.K., Wener K., Freedman R., Pandya S.S., et al. A fatal case of necrotizing pneumonia cause by community-acquired methicillin-resistant Staphylococcus aureus. Infect Dis Clin Pract 2005, 13:132-138.
44. Centers for Disease Controle and Prevention, (CDC) Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January, 2007. MMWR Morb Mortal Wkly Rep 2007, 56:325-329.
45. Torell E., Molin D., Tano E., Ehrenborg C., Ryden C. Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scand J Infect Dis 2005, 37:902-904.
46. Thomas B., Pugalenthi A., Chilvers M. Pleuropulmonary complications of PVL-positive Staphylococcus aureus infection in children. Acta Paediatr 2009, 98:1372-1375.
47. Joguet G., Perez J.M., Herrmann C., Strobel M. Lethal necrotizing pneumonia by Panton-Valentine leukociding-producing Staphylococcus aureus. Med Mal Infect 2003, 5:272-273.
48. Kravitz G.R., Dries D.J., Peterson M.L., Schlievert P.M. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005, 40:941-947.
49. Étienne J. Panton-Valentine leukocidin: a marker of severity for Staphylococcus aureus infection?. Clin Infect Dis 2005, 41:591-593.
50. Jarraud S., Mougel C., Thioulouse J., Lina G., Meugnier H., Forey F., et al. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 2002, 70:631-641.
51. Roberts S., O'Shea K., Morris D., Robb A., Morrison D., Rankin S. A real-time PCR assay to detect the Panton-Valentine Leukocidin toxin in staphylococci: screening Staphylococcus schleiferi subspecies coagulans strains from companion animals. Vet Microbiol 2005, 107:139-144.
52. Renwick L., Holmes A., Templeton K. Multiplex real-time PCR assay for the detection of meticillin-resistant Staphylococcus aureus and Panton-Valentine leukocidin from clinical samples. Methods Mol Biol 2013, 943:105-113.
53. Monecke S., Muller E., Buechler J., Rejman J., Stieber B., Akpaka P.E., et al. Rapid detection of Panton-Valentine leukocidin in Staphylococcus aureus cultures by monoclonal antibodies using a lateral flow assay. J Clin Microbiol 2012, 51:487-495.
54. Oishi K., Baba T., Nakatomi Y., Ito T., Hiramatsu K. A latex agglutination assay for specific detection of Panton-Valentine leukocidin. J Microbiol Methods 2008, 75:411-415.
55. Badiou C., Dumitrescu O., George N., Forbes A.R., Drougka E., Chan K.S., et al. Rapid detection of Staphylococcus aureus Panton-Valentine leukocidin in clinical specimens by enzyme-linked immunosorbent assay and immunochromatographic tests. J Clin Microbiol 2010, 48:1384-1390.
56. Bittar F., Ouchenane Z., Smati F., Raoult D., Rolain J.M. MALDI-TOF-MS for rapid detection of staphylococcal Panton-Valentine leukocidin. Int J Antimicrob Agents 2009, 34:467-470.
57. Dauwalder O., Carbonnelle E., Benito Y., Lina G., Nassif X., Vandenesch F., et al. Detection of Panton-Valentine toxin in Staphylococcus aureus by mass spectrometry directly from colony: time has not yet come. Int J Antimicrob Agents 2010, 36:193-194.
58. Li H.T., Zhang T.T., Huang J., Zhou Y.Q., Zhu J.X., Wu B.Q. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration 2011, 81:448-460.
59. Cabello H., Torres A., Celis R., El-Ebiary M., Puig de la Bellacasa J., Xaubet A., et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997, 10:1137-1144.
60. Sethi S., Murphy T.F. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-art review. Clin Microb Rev 2001, 14:336-363.
61. Nseir S., Cavestri B., Di Pompeo C., Diarra M., Brisson H., Lemyze M., et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008, 76:253-260.
62. Kahl B.C., Duebbers A., Lubritz G., Haeberle J., Koch H.G., Ritzerfeld B., et al. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol 2003, 41:4424-4427.
63. Sawicki G.S., Rasouliyan L., Ren C.L. The impact of MRSA on lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2009, 179:734-735. [author reply 5].
64. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182:627-632.
65. Besier S., Smaczny C., von Mallinckrodt C., Krahl A., Ackermann H., Brade V., et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol 2007, 45:168-172.
66. Haute Autorité de Santé (HAS). Conférence de consensus-Prise en charge du patient atteint de mucoviscidose. 2002.
67. Doring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91.
68. Haque N.Z., Arshad S., Peyrani P., Ford K.D., Perri M.B., Jacobsen G., et al. Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2012, 50:1640-1644.
69. Rello J., Ollendorf D.A., Oster G., Vera-Llonch M., Bellm L., Redman R., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122:2115-2121.
70. Brusselaers N., Labeau S., Vogelaers D., Blot S. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med 2012, 39:365-375.
71. Cercenado E., Marin M., Burillo A., Martin-Rabadan P., Rivera M., Bouza E. Rapid detection of Staphylococcus aureus in lower respiratory tract secretions from patients with suspected ventilator-associated pneumonia: evaluation of the Cepheid Xpert MRSA/SA SSTI assay. J Clin Microbiol 2012, 50:4095-4097.
72. Athanassa Z., Siempos I.I., Falagas M.E. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008, 31:625-632.
73. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe-Surveillance report 2011. 2012.
74. Farrell D.J., Castanheira M., Mendes R.E., Sader H.S., Jones R.N. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis 2012, 55:S206-S214.
75. Malhotra-Kumar S., Haccuria K., Michiels M., Ieven M., Poyart C., Hryniewicz W., et al. Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococcus species. J Clin Microbiol 2008, 46:1577-1587.
76. Ohara S., Malhotra-Kumar S., Haccuria K., Van Heirstraeten L., Ieven M., Goossens H. Novel rapid culture-based detection method for methicillin-resistant Staphylococcus [corrected] aureus. J Clin Microbiol 2008, 46:3181. [author reply 381-2].
77. Chang F.Y., Peacock J.E., Musher D.M., Triplett P., MacDonald B.B., Mylotte J.M., et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003, 82:333-339.
78. Bernardo K., Pakulat N., Fleer S., Schnaith A., Utermohlen O., Krut O., et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004, 48:546-555.
79. Conte J.E., Golden J.A., Kipps J., Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002, 46:1475-1480.
80. Dartois N., Castaing N., Gandjini H., Cooper A. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008, 20:28-35.
81. Farrell D.J., Flamm R.K., Jones R.N., Sader H.S. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagn Microbiol Infect Dis 2013, 75:86-88.
82. Silverman J.A., Mortin L.I., Vanpraagh A.D., Li T., Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005, 191:2149-2152.
83. Dumitrescu O., Boisset S., Badiou C., Bes M., Benito Y., Reverdy M.E., et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 2007, 51:1515-1519.
84. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60.
85. Sevransky J.E., Levy M.M., Marini J.J. Mechanical ventilation in sepsis-induced acute lung injury/acute respiratory distress syndrome: an evidence-based review. Crit Care Med 2004, 32:S548-S553.
86. Chidiac C. Systemic antibiotherapy for the treatment of lower respiratory tract infections. Community acquired pneumonia, acute exacerbation of obstructive chronic bronchitis. Med Mal Infect 2011, 41:221-228.
87. Gauduchon V., Cozon G., Vandenesch F., Genestier A.L., Eyssade N., Peyrol S., et al. Neutralization of Staphylococcus aureus Panton-Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004, 189:346-353.
88. Darenberg J., Soderquist B., Normark B.H., Norrby-Teglund A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004, 38:836-842.
89. Ek T., Andersson O., Kasemo A.U., Wede M., Nilsson P.A. PVL positive S.aureus as the cause of necrotizing pneumonia. Description of three severe cases in earlier healthy young persons. Lakartidningen 2007, 104:11-13.
90. Léophonte P., Chidiac C., Drugeon H.B., Strabach S., Cabrillac-Rives S., Chone C., et al. Treatment of exacerbations of chronic obstructive pulmonary disease with pristinamycin. Rev Mal Respir 2004, 21:261-271.
91. Goss C.H., Muhlebach M.S. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 2011, 10:298-306.
92. Smyth A., Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003, CD001912.
93. Bolton C.E., Ionescu A.A., Evans W.D., Pettit R.J., Shale D.J. Altered tissue distribution in adults with cystic fibrosis. Thorax 2003, 58:885-889.
94. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
95. Walkey A.J., O'Donnell M.R., Wiener R.S. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011, 139:1148-1155.
96. Wunderink R.G., Niederman M.S., Kollef M.H., Shorr A.F., Kunkel M.J., Baruch A., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
97. Sanchez Garcia M., De la Torre M.A., Morales G., Pelaez B., Tolon M.J., Domingo S., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303:2260-2264.
98. Welte T., Pletz M.W. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents 2010, 36:391-400.
99. Rubinstein E., Lalani T., Corey G.R., Kanafani Z.A., Nannini E.C., Rocha M.G., et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011, 52:31-40.
100. Fraser T.G., Fatica C., Scarpelli M., Arroliga A.C., Guzman J., Shrestha N.K., et al. Decrease in Staphylococcus aureus colonization and hospital-acquired infection in a medical intensive care unit after institution of an active surveillance and decolonization program. Infect Control Hosp Epidemiol 2010, 31:779-783.